About Ausel
Ausel is developing a product it calls the Ausel Cancer Test, meant to assess biomarkers linked to cancer. Ausel's case is that a breakthrough in cancer biomarker assessment is coming, though it has not given further detail.
Ausel is based in Carlsbad, California. Nicholas Ainslie is the company's chief executive officer and chief financial officer, and a director. Paul Shockley is chief operating officer and secretary, and a director.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 22, 2026 | Nov 4, 2026 | $120,000of $5.0M target | 1 | $120K | EquityRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Ausel in the News
Leadership Team
Executive officers and directors listed on Ausel's Form D filed Nov 4, 2026.
NA
PS
PP
Prisco Piscitelli
Chief Medical Officer
PA
Paul Ainslie
Chairman of the Board of Directors
RA
Robert Ainslie
Non-operating Founder